Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease.
Sabaté
M
M
Bosch
A
A
Pedrós
C
C
Figueras
A
A
D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001577:Benzophenones / Q000009:adverse effects* / Q000627:therapeutic use; D065098:Catechol O-Methyltransferase Inhibitors; D004791:Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009596:Nitrophenols; D010300:Parkinson Disease / Q000188:drug therapy*; D000077867:Tolcapone; D014820:Vitiligo / Q000139:chemically induced*
D000978:Antiparkinson Agents; D001577:Benzophenones; D065098:Catechol O-Methyltransferase Inhibitors; D004791:Enzyme Inhibitors; D009596:Nitrophenols; D007980:Levodopa; D000077867:Tolcapone